Among non-peptide antagonists, GLPG0187 has emerged as a novel therapy impeding glioma invasion and metastasis by inhibiting integrin αv and TGF-β in a completed phase I dose escalating study (Cirkel et al., 2016). Here, TGFB1 is linked to central nervous system cancer.